Shots:
- Genmab has entered into a transaction agreement to acquire Merus, incl. its lead asset petosemtamab, expanding its late-stage pipeline & accelerating Genmab’s shift to a wholly owned model
- As per the deal, Genmab will acquire Merus for $97 per share in an all-cash transaction, representing the deal value of ~$8B, with closing expected in the early Q1’26
- Petosemtamab, an EGFRxLGR5 BsAb, is in 2 P-III trials for 1 & 2/3L head & neck cancer, with interim data expected in 2026; Genmab anticipates a 2027 launch, pending results & approvals, plus plans to expand petosemtamab into earlier lines of therapy. P-II data presented at ASCO’25 showed improved ORR & mPFS
Ref: Genmab | Image: Merus| Press Release
Related News:- Roche to Acquire 89bio for ~$3.5B, Strengthening its CVRM Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
